
TG-46
CAS No. 936091-15-5
TG-46( —— )
Catalog No. M33688 CAS No. 936091-15-5
TG-46 (TG46) inhibits JAK2, FLT3, RET, JAK3 and can be used to study glaucoma.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 296 | Get Quote |
![]() ![]() |
5MG | 409 | Get Quote |
![]() ![]() |
10MG | 618 | Get Quote |
![]() ![]() |
25MG | 1021 | Get Quote |
![]() ![]() |
50MG | 1546 | Get Quote |
![]() ![]() |
100MG | 2286 | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameTG-46
-
NoteResearch use only, not for human use.
-
Brief DescriptionTG-46 (TG46) inhibits JAK2, FLT3, RET, JAK3 and can be used to study glaucoma.
-
DescriptionJAK-IN-35 (compound TG46) is a JAK2 inhibitor that canb be used in cancer research.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetJAK
-
RecptorJAK | FLT
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number936091-15-5
-
Formula Weight510.65
-
Molecular FormulaC26H34N6O3S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCc1cnc(Nc2ccc(CN3CCOCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Wenge Zhu, et al. Combination therapy for treating cancer. Patent WO2018187485A1.
molnova catalog



related products
-
JAK1-IN-31
JAK1-IN-31 is a potent and selective JAK1 inhibitor with Ki of 1.9 nM.
-
Decernotinib
Decernotinib (VX-509, VRT-831509) is a potent, selective, orally available JAK3 inhibitor with Ki of 2.5 nM and cellular IC50 of 50-170 nM.
-
Peficitinib
Peficitinib (ASP-015K, JNJ-54781532) is a potent JAK inhibitor with IC50s of 3.9 and 0.7 nM for JAK1 and JAK3 respectively; inhibits IL-2-dependent T cell proliferation in vitro and STAT5 phosphorylation in vitro and ex vivo.